KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Cash & Equivalents (2016 - 2025)

Novartis Ag's Cash & Equivalents history spans 12 years, with the latest figure at $2.6 billion for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 965.7% to $2.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 billion, a 965.7% increase, with the full-year FY2025 number at $2.6 billion, up 965.7% from a year prior.
  • Cash & Equivalents hit $2.6 billion in Q4 2025 for Novartis Ag, down from $11.5 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for NVS hit a ceiling of $13.9 billion in Q2 2022 and a floor of $5117.0 in Q2 2021.
  • Historically, Cash & Equivalents has averaged $5.1 billion across 5 years, with a median of $1.6 billion in 2023.
  • Biggest five-year swings in Cash & Equivalents: plummeted 100.0% in 2021 and later surged 270705391.5% in 2022.
  • Tracing NVS's Cash & Equivalents over 5 years: stood at $12.4 billion in 2021, then plummeted by 39.41% to $7.5 billion in 2022, then soared by 78.17% to $13.4 billion in 2023, then tumbled by 98.19% to $242.0 million in 2024, then skyrocketed by 965.7% to $2.6 billion in 2025.
  • Business Quant data shows Cash & Equivalents for NVS at $2.6 billion in Q4 2025, $11.5 billion in Q2 2025, and $242.0 million in Q4 2024.